jorgej_castillo@dfci.harvard.edu. Non-L265P MYD88 mutations have been described in WM patients, and testing requires sequencing of the entire MYD88 gene.8  In this case, with an elevated serum IgM level, a lymphoplasmacytic infiltrate of the bone marrow, and presence of the MYD88 L265P mutation, the diagnosis of WM is confirmed. Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study. The first step in the management of Waldenström macroglobulinemia (WM) is to properly establish the diagnosis. Hassab-El-Naby HMM, El-Khalawany M, Rageh MA. 2020 Sep 28;12(9):e10694. eCollection 2019 Oct. Gotoh Y, Aoyama Y, Tsunemine H, Idei Y, Mori A, Kodaka T, Iba S, Tomita A, Itoh T, Takahashi T. J Clin Exp Hematop. Ibrutinib is being evaluated in combination with chemoimmunotherapy, proteasome inhibitors, BCL2 inhibitors, and anti-CD38 antibodies. The importance of genetic factors is suggested by the observation of familial clustering of WM (McMaster, 2003). The management of Waldenström macroglobulinemia (WM) has evolved tremendously with recent genomic discoveries that correlate with clinical presentation and could help to tailor treatment approaches. The role of extramedullary invol … Hematology Am Soc Hematol Educ Program 2020; 2020 (1): 372–379. The acquisition of BTK mutations has been associated with resistance to covalent BTK inhibitors in patients with WM.42  Second-generation noncovalent BTK inhibitors (eg, vecabrutinib, LOXO-305, ARQ-531) are being investigated in WM patients. The cancer cells make large amounts of an abnormal protein (called a macroglobulin).Another name for WM is lymphoplasmacytic lymphoma.This condition used to be called Waldenstrom’s macroglobulinemia, so some people refer to it as Waldenstrom’s. Immunoglobulin M (IgM) monoclonal gammopathies show considerable variability, involving three different stages of presentation: IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), asymptomatic Waldenström's macroglobulinemia (AWM), and symptomatic WM (SWM). Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL). Der Morbus Waldenström (MW), auch Makroglobulinämie oder Immunozytom genannt, ist eine maligne Lymphomerkrankung.Sie wird zu den indolenten (d. h. langsam fortschreitenden und wenig Symptome verursachenden) B-Zell-Non-Hodgkin-Lymphomen gezählt, und zwar unter die Oberkategorie der lymphoplasmozytischen Lymphome. JAAD Case Rep. 2020 Jun 21;6(8):771-775. doi: 10.1016/j.jdcr.2020.06.024. Waldenstrom's macroglobulinemia is a rare type of cancer; specifically it is a type of non-Hodgkin Lymphoma. Three years later, the patient presented with recurrent nosebleeds and progressive fatigue affecting his activities. An algorithm for the management of ibrutinib-related atrial fibrillation has been published.32  About 20% of WM patients who discontinue ibrutinib temporarily might experience withdrawal symptoms, such as fever, night sweats, and fatigue, which could be managed with low doses of steroids during the hold.33  An increase in serum IgM levels can also be seen during holds and should not be considered disease progression, because serum IgM levels decrease promptly after restarting ibrutinib. Given the symptoms of hyperviscosity, prompt initiation of plasmapheresis is appropriate to prevent potential thrombotic and/or hemorrhagic complications.13  Plasmapheresis, however, does not constitute definitive treatment of active WM and should be used as a transition toward primary therapy.13  In this setting, screening tests for acquired von Willebrand disease (vWD), such as von Willebrand antigen, ristocetin cofactor, and factor VIII levels, should be performed. Waldenstrom macroglobulinemia (WM) is a malignant B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and hypersecretion of monoclonal immunoglobulin M (IgM) protein (review by Vijay and Gertz, 2007). Copyright ©2020 by American Society of Hematology, Monoclonal Gammopathies of Determined Significance, Treatment options in the relapsed setting, https://doi.org/10.1182/hematology.2020000121, Cytopenias, infections, myeloid neoplasms, Cytopenias, bleeding, arrhythmias, hypertension. At the end of therapy, the patient’s blood counts normalized, his lymphadenopathy resolved, and his serum IgM level was 1400 mg/dL, consistent with a partial response. immunoglobulin-producing plasma cell. Within 3 months of therapy, the patient’s hemoglobin normalized, and his serum IgM level decreased to 320 mg/dL, consistent with a VGPR to therapy. Waldenström macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. Diagnosis . Waldenstrom's macroglobulinemia symptoms begins in the B-lymphocytes which are white blood cells. The flow characteristics of the cells can help distinguish Waldenström's macroglobulinemia from multiple myeloma. D, dexamethasone; MRR, major response rate; NR, not reported; R, rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubucin, vincristine, and prednisone; RR, relapsed/refractory; TN, treatment naive. Final report of the PIVOTAL Trial (NCT01614821), Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions, The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis, Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia, iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia, Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia, Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia, Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia, Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study, Updated safety and efficacy data in a phase 1/2 trial of patients with Waldenström macroglobulinaemia (WM) treated with the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111), ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM), Major responses in MYD88 wildtype (MYD88WT) Waldenström macroglobulinemia (WM) patients treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111), Phase 2 study of tirabrutinib (ONO/GS-4059), a second-generation Bruton's tyrosine kinase inhibitor, monotherapy in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia, Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN), Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia, Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenström macroglobulinemia, Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies.
2020 waldenstrom macroglobulinemia immunoglobulin